Document is current

Article History

Received: 11 March 2026

Accepted: 13 May 2026

First Online: 6 June 2026

Declarations

:

: This study and manuscript have been promoted by Novo Nordisk Pharma SA. Alberto Martín-Lorenzo is an employee of Novo Nordisk Pharma SA and Sara Larsen is an employee of Novo Nordisk A/S. Ferran Pérez-Alcántara, Ened Rodríguez-Urgellés and Miquel Sastre-Belío are employees of Cencora Pharmalex Spain, which has received a consulting fee from Novo Nordisk Pharma SA. Andreu Altés reports (a) honoraria for lectures from AstraZeneca, Esteve, Lilly, Gebro, Sankyo-Daichii, Glaxo, Novo Nordisk, Sanofi and Boheringer Ingelheim; (b) consulting fees from Novo Nordisk and Lilly. Óscar Moreno-Pérez reports (a) honoraria for lectures from AstraZeneca, Novo Nordisk, Bayer and Lilly; (b) consulting fees from AstraZeneca and Sanofi. Miriam Sandín reports (a) honoraria for lectures from AstraZeneca, Ferrer, Novo Nordisk, Sanofi and Amgen; (b) consulting fees from AstraZeneca, Ferrer, Amgen, Novo Nordisk and Daiichi Sankyo. Josep Vidal reports (a) honoraria for lectures from Boehringer Ingelheim, Novo Nordisk and Lilly; (b) consulting fees from Novo Nordisk and Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors have not received any payment for the authorship of this manuscript.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.